stella
beta
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies — Stella
Recruiting
Back to Hematologic Neoplasms trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
National Institutes of Health Clinical Center, Bethesda, Maryland
View full record on ClinicalTrials.gov